<DOC>
	<DOC>NCT00768612</DOC>
	<brief_summary>This study will evaluate the clinical safety and tolerability of vabicaserin in Japanese subjects that have a sudden worsening of their symptoms of schizophrenia. The study will also assess the efficacy of vabicaserin and compare it to risperidone.</brief_summary>
	<brief_title>Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Male and female subjects between &gt;=20 and =&lt;65 years of age Current diagnosis and DSMIVTR diagnosis of schizophrenia type (295.10, 295.30 and 295.90) Total PANSS score &gt;=70 and =&lt; 120 Subjects who are hospitalized against their will Current Axis I primary psychiatric diagnosis other than schizophrenia A score of 3 on CDSS question 8 which pertains to suicide</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Acute, Schizophrenia, Phase2a, Vabicaserin</keyword>
</DOC>